Consumer Product Safety |
|
|
Clinical Trial: A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches - 1
This study is not yet open for patient recruitment.
Verified by National Institute on Drug Abuse (NIDA) August 2005
Purpose
| Condition |
|---|
| Tobacco Use Disorder nicotine |
MedlinePlus related topics: Smoking
Study Type: Observational
Study Design: Natural History, Cross-Sectional, Random Sample, Prospective Study
Official Title: Usage Patterns of OTC Nicotine Patches: Consumer Survey
Expected Total Enrollment: 600
Study start: September 2005
The nicotine patch is an effective aid for smoking cessation. Since 1996, the nicotine patch has been re-classified from prescription to over-the-counter (OTC) status in the United States. Unlike prescription medications, post-marketing surveillance does not exist for OTC medications. The purpose of this study is to describe the characteristics of consumers who purchase OTC nicotine patches from community pharmacies and to determine the factors associated with appropriate use of nicotine patches.
This prospective, cross-sectional, observational study will include a survey of 600 consumers who purchase OTC nicotine patches at a random sample of 30 community retail pharmacies. Consumers will be recruited by an ad located in the pharmacy next to the nicotine patch product. Participants will fill out a self-administered, anonymous questionnaire at the time of OTC nicotine patch purchase at the pharmacy counter. The questionnaire will gather information about demographics, medical history, smoking history, attitudes toward the nicotine patch, and motivation to quit smoking. No study visits will be required for this study.
Eligibility
Accepts Healthy Volunteers
Inclusion Criteria:
- Purchased OTC nicotine patch (NicoDerm CQ Step I, II, III or Sav-on Nicotine Patch) for personal use
Exclusion Criteria:
- Purchased OTC nicotine patch for someone other than self (e.g., friend or family member)
Location and Contact Information
California
Department of Family and Preventive Medicine, La Jolla, California, 92093, United States
Chih-Wen Shi, M.D., M.S., Principal Investigator, University of California, San Diego
More Information
Last Updated: August 24, 2005
Record first received: August 23, 2005
ClinicalTrials.gov Identifier: NCT00134927
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-08-30
Resources
- Agencies Team Up in War Against Internet Health Fraud (Food and Drug Administration, HHS)
- An FDA Guide to Choosing Medical Treatments (Office of Consumer Affairs, OEA, FDA,)

Not Signed In -

